Company profile: Circio
1.1 - Company Overview
Company description
- Provider of active immunotherapy cancer vaccines for post-operation treatments, including TG01, a peptide-based vaccine targeting KRAS/RAS driver mutations in clinical trials for RAS-mutated pancreatic cancer, lung cancer, and multiple myeloma, and circVec, a genetic medicine platform producing multifunctional circular RNA from DNA and viral vectors with enhanced, durable protein expression versus classic mRNA systems.
Products and services
- TG01: a peptide-based cancer vaccine targeting KRAS driver mutations, administered post-operation to trigger immune recognition of cancer-specific RAS mutations and kill cells, in phase I/II for pancreatic, lung, multiple myeloma
- Active Immunotherapy Cancer Vaccines: clinical-stage post-operative regimens that activate the immune system to recognize cancer-specific RAS mutations and eradicate residual cancer cells in resectable pancreatic cancer patients
- CircVec: a modular genetic medicine platform using cassette design to engineer multifunctional circular RNA from DNA and viral vectors, achieving enhanced durable protein expression than classic mRNA vector systems.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Circio
Theraclion
HQ: France
Website
- Description: Provider of high-intensity focused ultrasound (HIFU) echotherapy medical equipment, combining HIFU with standard ultrasound for non-invasive treatment and target localization. Solutions include SONOVEIN for varicose veins; ECHOPULSE for thyroid nodules and breast fibroadenoma; CURE-OP for combinational cancer therapy integrating ultrasound with radiotherapy; and EPack single-use disposables for cooling and coupling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclion company profile →
WntResearch
HQ: Sweden
Website
- Description: Provider of anti-metastatic cancer therapies targeting WNT5A signaling. Pipeline includes Foxy-5, a peptide drug candidate that mimics WNT5A to reduce cancer cell mobility and spread (Phase I; reconstitutes Wnt-5a effects in breast cancer cells), and Box-5, a peptide in preclinical development that antagonizes Wnt-5a.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full WntResearch company profile →
Lindis Blood Care
HQ: Germany
Website
- Description: Provider of a medical device for removing cancer cells from intraoperative blood during cancer surgeries to enable autologous blood transfusion (CATUVAB), and a multicenter clinical certification study (REMOVE) assessing the device’s efficacy and safety in tumor cell removal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lindis Blood Care company profile →
ScreenPoint Medical
HQ: The Netherlands
Website
- Description: Provider of deep learning and image analysis technology for automated reading of mammograms and digital breast tomosynthesis. Offers Transpara software that assists radiologists by categorizing and prioritizing exams, differentiating those with a high probability of suspicious findings, and providing workflow enhancements, combining machine learning advances with very large, well-curated digital image databases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ScreenPoint Medical company profile →
Galecto
HQ: Denmark
Website
- Description: Provider of clinical-stage small molecule therapies for fibrosis and cancer. Develops inhibitors including GB0139, an inhaled galectin-3 inhibitor for severe fibrotic lung diseases such as idiopathic pulmonary fibrosis; GB1211, an oral galectin-3 inhibitor for decompensated cirrhosis; and GB2064, a LOXL2 inhibitor for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galecto company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Circio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Circio
2.2 - Growth funds investing in similar companies to Circio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Circio
4.2 - Public trading comparable groups for Circio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →